|   |
|--------|

| x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
|---|------------------------------------------------------|

|   | SECURITIES EXCHANGE ACT OF 1934 |
|--------|---------------------------------|

| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
|---|----------------------------------------------------------|

|   | SECURITIES EXCHANGE ACT OF 1934 |
|--------|---------------------------------|

| Delaware                                                       | 94-3148201                           |
|----------------------------------------------------------------|--------------------------------------|
| (State or other jurisdiction of Incorporation or organization) | (I.R.S. Employer Identification No.) |
|                                                           |                                 |
| 995 E. Arques AvenueSunnyvale, CA                              | 94085-4521                           |
| (Address of principal executive offices)                       | (Zip code)                           |
|                                                           |                                 |

| Title of Each Class             | Name of Each Exchange onWhich Registered |
|---------------------------------|------------------------------------------|
| Common Stock, $0.0001 par value | Nasdaq Capital Market                    |

----

Table of Contents

----

Table of Contents

----

Table of Contents

Annual 

| PART III  |                                                                                           | PAGE  |
|----------------|------------------------------------------------------------------------------------------------|------------|
| Item 10.       | Directors, Executive Officers and Corporate Governance                                         | 1          |
| Item 11.       | Executive Compensation                                                                         | 6          |
| Item 12.       | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 25         |
| Item 13.       | Certain Relationships and Related Transactions, and Director Independence                      | 28         |
| Item 14.       | Principal Accountant Fees and Services                                                         | 29         |
|           |                                                                                           |       |
| PART IV   |                                                                                           |       |
| Item 15.       | Exhibits and Financial Statement Schedules                                                     | 30         |
|           |                                                                                           |       |
|           |                                                                                           |       |

----

Table of Contents

PART 

| Item 10. | Directors, Executive Officers and Corporate Governance |
|----------|--------------------------------------------------------|

| Name                     |   | Age |   | Position(s) with the Company |   | Director Since |
|--------------------------|--------|-----|--------|------------------------------|--------|----------------|
| Robert W. Duggan         |   | 70  |   | Director, Chairman and CEO   |   | 2007           |
| Robert F. Booth, Ph.D.   |   | 61  |   | Director                     |   | 2010           |
| Kenneth A. Clark         |   | 56  |   | Director                     |   | 2012           |
| Eric H. Halvorson        |   | 65  |   | Director                     |   | 2011           |
| Minesh P. Mehta, M.D.    |   | 57  |   | Director                     |   | 2008           |
| David D. Smith, Ph.D.    |   | 44  |   | Director                     |   | 2008           |
| Richard A. van den Broek |   | 49  |   | Director                     |   | 2009           |

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Name                                |    | Age |    | Position                                          |
|-------------------------------------|--------------|-----|--------------|---------------------------------------------------|
| Robert W. Duggan                    |    | 70  |    | Chairman of the Board and Chief Executive Officer |
| Mahkam (Maky) Zanganeh, D.D.S., MBA |    | 44  |    | Chief Operating Officer                           |
| Manmeet S. Soni                     |    | 37  |    | Chief Financial Officer and Treasurer             |
| Shawn Tomasello                     |         | 56  |         | Chief Commercial Officer                          |
| Heow Tan                            |    | 56  |    | Chief of Quality and Technical Operations         |

----

Table of Contents

----

Table of Contents

| Item 11. | Executive Compensation |
|----------|------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Name                         |    | 2014 Target Bonus as% of salary |   |   | 2014 Annual Cash Incentive Paid |   |                                                                                                                  | 2014 Bonus Paidas % of salary |   |
|------------------------------|--------------|------------------------------------------------|--------|--------|-------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|--------|
| Current Officers:            |    |                                           |   |   |                                      |   |                                                                                                                       |                                    |   |   |   |   |
| Robert W. Duggan             |    |  0%                                       |   |   |                                      |   | $                    - |                                    |   |   | 0% |   |
| Mahkam Zanganeh, D.D.S., MBA |    |  60%                                      |   |   |                                      |   | 378,769                                                                                                                    |                                    |   |   | 75% |   |
| Manmeet Soni                 |    |  60%                                      |   |   |                                      |   | 310,290                                                                                                                    |                                    |   |   | 75% |   |
| Shawn Tomasello(1)           |    |  60%                                      |   |   |                                      |   | 142,154                                                                                                                    |                                    |   |   | 60% |   |
| Heow Tan                     |    |  50%                                      |   |   |                                      |   | 213,629                                                                                                                    |                                    |   |   | 55% |   |
| Former Officer:              |    |                                           |   |   |                                      |   |                                                                                                                       |                                    |   |   |   |   |
| Paula Boultbee               |    |  0%                                       |   |   |                                      |   |                    -        |                                    |   |   | 0% |   |

----

Table of Contents

----

Table of Contents

|   | (i) | $261.25 in cash; |
|--------|-----|------------------|

|   | (ii) | a number of shares of AbbVie common stock equal to (x) $261.25 divided by (y) the volume weighted average sale price per share of AbbVie common stock as reported on the New York Stock Exchange for the ten consecutive trading days ending on and including the second trading day prior to the final expiration of the offer, as calculated by Bloomberg Financial LP under the function “ABBV UN Equity AQR” (as it may be extended in accordance with the Merger Agreement) (such price, the “AbbVie Trading Price”); or |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | $152.25 in cash and a number of shares of AbbVie common stock equal to (x) $109.00 divided by (y) the AbbVie Trading Price. |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  Name                     |   | Number ofPharmacyclicsSharesOwned(1) |                |         | MergerConsiderationfor OwnedShares ($)(2) |     |                | SharesSubject toOutstandingOptions(3) |   |   | OptionCashPayment($)(4) |         |   | Number ofOutstandingRestrictedStockUnits(5) |                |         | RSU CashPayment($)(6) |   |                | Total Payment($) |   |
|-------------------------------------|--------|--------------------------------------|---------------------|--------------|-------------------------------------------|----------|---------------------|---------------------------------------|--------|--------|-------------------------|--------------|--------|---------------------------------------------|---------------------|--------------|-----------------------|--------|---------------------|-----------------------|--------|
| Directors                           |   |                                 |                |         |                                      |     |                |                                  |   |   |                    |         |   |                                        |                |         |                  |   |                |                  |   |   |   |   |   |   |   |   |
|   Robert F. Booth, Ph.D.       |   |                                 | —   |    |                                      |   $ | —   |                             |   |   | 66,549                  |    |   |   $                                    | 15,662,411          |    |                  |   | 10,000              |             |   |   | 2,612,500 |    |   |   $ | 18,274,911 |    |
|   Eric H. Halvorson            |   |                                 | 1,000               |    |                                      |     | 261,250             |                             |   |   | 31,474                  |    |   |                                        | 6,692,738           |    |                  |   | —   |             |   |   | —   |    |   |   | 6,953,988 |    |
|   Kenneth Clark, J.D.          |   |                                 | —   |    |                                      |     | —   |                             |   |   | 24,619                  |    |   |                                        | 4,846,880           |    |                  |   | —   |             |   |   | —   |    |   |   | 4,846,880 |    |
|   Minesh P. Mehta, M.D.        |   |                                 | —   |    |                                      |     | —   |                             |   |   | 30,131                  |    |   |                                        | 6,462,445           |    |                  |   | —   |             |   |   | —   |    |   |   | 6,462,445 |    |
|   David D. Smith, Ph.D.        |   |                                 | 3,000               |    |                                      |     | 783,750             |                             |   |   | 182,110                 |    |   |                                        | 45,689,234          |    |                  |   | —   |             |   |   | —   |    |   |   | 46,472,984 |    |
|   Richard A. van den Broek     |   |                                 | 29,610              |    |                                      |     | 7,735,613           |                             |   |   | 100,342                 |    |   |                                        | 24,265,415          |    |                  |   | —   |             |   |   | —   |    |   |   | 32,001,028 |    |
| Executive Officers                  |   |                                 |                |         |                                      |     |                |                                  |   |   |                    |         |   |                                        |                |         |                  |   |                |                  |   |   |   |   |   |   |   |   |
|   Robert W. Duggan*            |   |                                 | 13,599,690          |    |                                      |     | 3,552,919,013       |                             |   |   | —       |    |   |                                        | —   |    |                  |   | —   |             |   |   | —   |    |   |   | 3,552,919,013 |    |
|   Mahkam Zanganeh, D.D.S., MBA |   |                                 | 428,281             |    |                                      |     | 111,888,411         |                             |   |   | 466,569                 |    |   |                                        | 108,783,820         |    |                  |   | 15,000              |             |   |   | 3,918,750 |    |   |   | 224,590,981 |    |
|   Manmeet S. Soni              |   |                                 | 856                 |    |                                      |     | 223,630             |                             |   |   | 92,902                  |    |   |                                        | 15,464,917          |    |                  |   | 54,000              |             |   |   | 14,107,500 |    |   |   | 29,796,047 |    |
|   Heow Tan                     |   |                                 | 7,994               |    |                                      |     | 2,088,433           |                             |   |   | 151,608                 |    |   |                                        | 31,523,994          |    |                  |   | —   |             |   |   | —   |    |   |   | 33,612,427 |    |
|   Shawn Tomasello              |   |                                 | 7,503               |    |                                      |     | 1,960,159           |                             |   |   | 100,000                 |    |   |                                        | 13,936,000          |    |                  |   | 50,000              |             |   |   | 13,062,500 |    |   |   | 28,958,659 |    |

----

Table of Contents

| * | Mr. Duggan is both a director and an executive officer. Mr. Duggan does not hold any options or restricted stock units and will not receive any option cash payment or RSU cash payment. |
|---|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (1) | Based on the number of shares owned (directly or indirectly) as of March 31, 2015. |
|-----|------------------------------------------------------------------------------------|

| (2) | Equals (i) the corresponding number of owned Pharmacyclics shares multiplied by (ii) the merger consideration. |
|-----|--------------------------------------------------------------------------------------------------------------------------|

| (3) | Number shown is the number of Pharmacyclics shares subject to outstanding options (whether vested or unvested) as of March 31, 2015. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------|

| (4) | Equals, with respect to all option awards held by the applicable director or executive officer listed in the “Shares Subject to Outstanding Options” column, (i) the number of shares subject to such option award multiplied by (ii) the all-cash consideration minus the exercise price applicable to such option award. The portions of the amounts in this column that will not become payable on the effective time of the first merger (unless the director or executive officer experiences an equity termination upon the effective time of the first merger) are as follows: $51,928 (Dr. Booth, Mr. Halvorson, Mr. Clark, Dr. Mehta, Dr. Smith, and Mr. van den Broek), $0 (Dr. Zanganeh), $748,688 (Mr. Soni), $0 (Mr. Tan), and $0 (Ms. Tomasello). For options that are unvested immediately before the effective time of the first merger (after taking into account the vesting acceleration described in the “—Consideration for Options” section above), the corresponding option cash payment will be paid in accordance with the corresponding option’s vesting terms and any unpaid portion of the option cash payment as of December 31 following the effective time of the first merger will be paid in a lump sum at that time subject to the applicable award holder continuing to provide services to AbbVie or its subsidiaries through such date (unless the applicable award holder experiences an equity termination prior to such time, in which case the option cash payment will be paid upon such equity termination). Such amounts for any non-employee director will become payable upon the non-employee director ceasing to be a director and service provider of Pharmacyclics after the effective time of the first merger. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5) | Number shown is the number of outstanding restricted stock units as of March 31, 2015. |
|-----|----------------------------------------------------------------------------------------|

| (6) | Equals (i) the corresponding number listed in the “Number of Outstanding Restricted Stock Units” column multiplied by (ii) the all-cash consideration. The portions of the amounts in this column that will not become payable on the effective time of the first merger (unless the director or executive officer experiences an equity termination upon the effective time of the first merger) are as follows: $1,306,250 (Dr. Booth), $1,959,375 (Dr. Zanganeh), $2,873,750 (Mr. Soni), $0 (Mr. Tan) and $0 (Ms. Tomasello). For restricted stock units that are unvested immediately before the effective time of the first merger (after taking into account the vesting acceleration described in the “—Consideration for Restricted Stock Units” section above), the corresponding RSU cash payment will be paid in accordance with the corresponding restricted stock unit’s vesting terms and any unpaid portion of the RSU cash payment as of December 31 following the effective time of the first merger will be paid in a lump sum at that time subject to the applicable award holder continuing to provide services to AbbVie or its subsidiaries through such date (unless the applicable award holder experiences an equity termination prior to such time, in which case the RSU cash payment will be paid upon such equity termination). Such amount for Dr. Booth, who is a consultant and a non-employee director of Pharmacyclics, will become payable to Dr. Booth in accordance with the corresponding restricted stock unit’s vesting terms and any unpaid portion of the RSU cash payment as of December 31 following the effective time of the first merger will be paid in a lump sum at that time, subject to Dr. Booth’s continued service with AbbVie or its subsidiaries (unless Dr. Booth experiences an earlier equity termination (in all capacities, including as both a consultant and a director) prior to such time, in which case this amount will be paid upon such equity termination). |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

| Name and Principal Position                                                 | Fiscal     |   | Salary(1) |    |   | Bonus  |    |    | Option Awards(2) |   |    | Stock Awards(2) |   |   | All Other Compensation |      |   | Total  |    |
|-----------------------------------------------------------------------------|------------|--------|-----------|---------|--------|--------|---------|---------|------------------|--------|---------|-----------------|--------|--------|------------------------|-----------|--------|--------|---------|
|                                                                        | Year       |   | ($)       |    |   | ($)    |    |    | ($)              |   |    | ($)             |   |   | ($)                    |      |   | ($)    |    |
| Current Officers:                                                           |       |   |      |    |   |   |    |    |             |   |    |            |   |   |                   |      |   |   |    |
| Robert W. Duggan, Chairman and Chief Executive Officer (3)             | 12/31/2014 |   |  $   | -       |   |   |  $ | -       |             |   |  $ | -               |   |   |  $                | -         |   |   |  $ | - |   |   |  $ | - |   |
|                                                                        | 12/31/2013 |   |      | -       |   |   |    | -       |             |   |    | -               |   |   |                   | -         |   |   |    | - |   |   |   | - |   |
|                                                                        | 12/31/2012 |   |      | -       |   |   |    | -       |             |   |    | -               |   |   |                   | -         |   |   |    | - |   |   |   | - |   |
|                                                                        | 6/30/2012  |   |      | -       |   |   |    | -       |             |   |    | -               |   |   |                   | -         |   |   |    | - |   |   |   | - |   |
|                                                                        |       |   |      |    |   |   |    |    |             |   |    |            |   |   |                   |      |   |   |    |   |   |   |   |   |   |
| Mahkam Zanganeh, D.D.S., MBA, Chief Operating Officer                       | 12/31/2014 |   |      | 514,440 |   |   |    | 378,769 |             |   |    | 5,438,791       | (4)    |   |                   | -         |   |   |    | 5,160 | (5) |   |   | 6,337,160 |   |
|                                                                        | 12/31/2013 |   |      | 489,231 |   |   |    | 360,000 |             |   |    | 3,861,276       | (4)    |   |                   | -         |   |   |    | 660 | (6) |   |   | 4,711,167 |   |
|                                                                        | 12/31/2012 |   |      | 247,308 |   |   |    | 1,500   |             |   |    | 5,531,912       | (4)    |   |                   | -         |   |   |    | 17,732 | (7) |   |   | 5,798,452 |   |
|                                                                        | 6/30/2012  |   |      | 359,773 |   |   |    | 6,456   |             |   |    | 84,466          | (4)    |   |                   | -         |   |   |    | 59,181 | (7) |   |   | 509,876 |   |
|                                                                        |       |   |      |    |   |   |    |    |             |   |    |            |   |   |                   |      |   |   |    |   |   |   |   |   |   |
| Manmeet S. Soni, Chief Financial Officer and Treasurer (8)             | 12/31/2014 |   |      | 421,565 |   |   |    | 310,290 |             |   |    | 1,182,258       | (4)    |   |                   | 1,481,039 | (4)    |   |    | 123,110 | (9) |   |   | 3,518,262 |   |
|                                                                        | 12/31/2013 |   |      | 282,327 |   |   |    | 258,750 |             |   |    | 482,852         | (4)    |   |                   | -         |   |   |    | 3,518 | (5) |   |   | 1,027,447 |   |
|                                                                        |       |   |      |    |   |   |    |    |             |   |    |            |   |   |                   |      |   |   |    |   |   |   |   |   |   |
| Shawn Tomasello, Chief Commercial Officer (10)                              | 12/31/2014 |   |      | 236,923 |   |   |    | 142,154 |             |   |    | 5,798,690       | (11)   |   |                   | 7,618,125 | (11)   |   |    | 45,090 | (12) |   |   | 13,840,982 |   |
|                                                                        |       |   |      |    |   |   |    |    |             |   |    |            |   |   |                   |      |   |   |    |   |   |   |   |   |   |
| Heow Tan, Chief of Quality and Technical Operations                         | 12/31/2014 |   |      | 388,417 |   |   |    | 213,629 |             |   |    | 3,372,965       | (4)    |   |                   | -         |   |   |    | 5,838 | (5) |   |   | 3,980,849 |   |
|                                                                        | 12/31/2013 |   |      | 374,308 |   |   |    | 330,000 | (13)             |   |    | 1,371,247       | (4)    |   |                   | -         |   |   |    | 4,518 | (5) |   |   | 2,080,073 |   |
|                                                                        |       |   |      |    |   |   |    |    |             |   |    |            |   |   |                   |      |   |   |    |   |   |   |   |   |   |
| Former Officer:                                                             |       |   |      |    |   |   |    |    |             |   |    |            |   |   |                   |      |   |   |    |   |   |   |   |   |   |
| Paula Boultbee, Former Executive Vice President of Sales and Marketing (14) | 12/31/2014 |   |      | 157,506 |   |   |    | -       |             |   |    | 4,443,000       | (4)    |   |                   | -         |   |   |    | 1,476 | (6) |   |   | 4,601,982 |   |
|                                                                        | 12/31/2013 |   |      | 320,000 |   |   |    | 176,000 |             |   |    | 2,066,879       | (4)    |   |                   | -         |   |   |    | 3,488 | (6) |   |   | 2,566,367 |   |

| (1) | Includes amounts earned but deferred at the election of the Named Executive Officer, such as salary deferrals under the Company’s 401(k) plan.  |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| (2) | The Company’s share-based compensation program includes incentive and non-statutory stock options and stock awards consisting of restricted stock units (RSUs). The amounts set forth under this column represent the aggregate grant date fair value of the option awards or stock awards granted in each fiscal year for financial reporting purposes under Statement of Financial Accounting Standards ASC Topic 718, “Stock Compensation,” disregarding the estimate of forfeitures. The Company’s methodology, including its underlying estimates and assumptions used in calculating these values, is set forth in Note 9 to its audited financial statements included in its Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2014. During the fiscal year ended December 31, 2014, December 31, 2013, the six month transition period ended December 31, 2012 and the fiscal year ended June 30, 2012, certain executive officers of the Company were granted performance-based options by the Company’s Compensation Committee under the 2014 and/or 2004 Plan, however, since performance criteria have not yet been set for certain tranches of these options, the fair value of such tranches is zero. For the year ended December 31, 2014, certain executive officers of the Company were granted performance-based RSUs under the 2014 and/or 2004 Plan, however, since performance criteria have not been set for certain tranches of these RSUs, the fair value of such tranches is zero.  |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | Mr. Duggan has declined any compensation from the Company. Mr. Duggan became the Company’s Interim Chief Executive Officer on September 10, 2008 and became the Company’s Chief Executive Officer on February 12, 2009.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

| (4) | The amount shown includes the portion of option and/or stock awards with performance-based vesting conditions for which the established performance conditions were established during the period. The grant date fair value was calculated using the probable outcome of the established performance conditions which approximated the highest level of achievement. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5) | Consists of the Company’s matching contributions under its 401(k) plan and insurance premiums paid by the Company. |
|-----|--------------------------------------------------------------------------------------------------------------------------|

| (6) | Consists of insurance premiums paid by the Company. |
|-----|-----------------------------------------------------|

| (7) | Consists of payments by the Company for Dr. Zanganeh’s local housing and related costs. |
|-----|-----------------------------------------------------------------------------------------------|

| (8) | Mr. Soni was promoted to Chief Financial Officer on February 4, 2014. Mr. Soni has served as the Company’s Principal Financial Officer and Principal Accounting Officer since August 16, 2013. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (9)    | Amount consists of $118,016 of relocation expenses paid by the Company, $4,500 of the Company’s matching contribution under its 401(k) plan and $594 of insurance premiums paid by the Company. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                  |
| (10)   | Ms. Tomasello was appointed Chief Commercial Officer on August 18, 2014.                                                                                                                         |
| (11)   | Amount represents the grant date fair value of Ms. Tomasello’s new hire option awards and stock awards granted on August 18, 2014.                                                         |
| (12)   | Amount consists of $44,108 of relocation expenses and $982 of insurance premiums paid by the Company.                                                                                                 |

| (13)   | Consists of $285,000 paid to Mr. Tan under the Company’s corporate bonus plan and a $45,000 bonus earned by Mr. Tan based on the achievement of certain performance targets set forth in his employment agreement.  |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (14)   | Ms. Boultbee served as the Company’s Executive Vice President of Sales and Marketing until May 20, 2014.                                                                                                                 |
|   |                                                                                                                                                                                                                           |

----

Table of Contents

|                         |       |   |                                                                                  |   |   | Estimated future payouts under equity incentive plan awards |   |   |   |   |   |    |   |   |                                                       |   |   |                                                             |   |
|------------------------------|------------|--------|---------------------------------------------------------------------------------------|--------|--------|-------------------------------------------------------------|--------|--------|--------|--------|--------|---------|--------|--------|------------------------------------------------------------|--------|--------|------------------------------------------------------------------|--------|
| Name                         | Grant Date |   | Date of Compensation Committee action to grant awards with performance conditions (1) |   |   | Threshold                                                   |   |   | Target |   |   | Maximum |   |   | All other stock awards: number of shares of stock or units |   |   | All other option awards: number of securities underlying options |   |   | Exercise or base price of option awards ($) |   |   | Grant date fair value of stock and option awards ($) |   |
| Robert W. Duggan             |       |   |                                                                                  |   |   |                                                        | -      |   |   |   | -      |    |   |   | -                                                          |   |   |                                                             | -      |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |       |   |                                                                                  |   |   |                                                        |   |   |   |   |   |    |   |   |                                                       |   |   |                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Mahkam Zanganeh, D.D.S., MBA | 3/24/2014  |   | 4/11/2010                                                                             |   |   |                                                        | -      |   |   |   | 9,375  | (2)     |   |   | 9,375                                                      | (2)    |   |                                                             | -      |   |   |   | - |   |   | $ | 7.19 |   |   | $ | 1,001,250 |   |
|                         | 3/24/2014  |   | 12/1/2011                                                                             |   |   |                                                        | -      |   |   |   | 22,917 | (3)     |   |   | 22,917                                                     | (3)    |   |                                                             | -      |   |   |   | - |   |   |   | 14.92 |   |   |   | 2,274,512 |   |
|                         | 3/24/2014  |   | 10/26/2012                                                                            |   |   |                                                        | -      |   |   |   | 29,167 | (4)     |   |   | 29,167                                                     | (4)    |   |                                                             | -      |   |   |   | - |   |   |   | 61.60 |   |   |   | 1,782,104 |   |
|                         | 4/2/2014   |   | 4/2/2014                                                                              |   |   |                                                        | -      |   |   |   | 7,500  | (5)     |   |   | 7,500                                                      | (5)    |   |                                                             | -      |   |   |   | - |   |   |   | 102.22 |   |   |   | 380,925 |   |
|                         |       |   |                                                                                  |   |   |                                                        |   |   |   |   |   |    |   |   |                                                       |   |   |                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Manmeet S. Soni              | 3/24/2014  |   | 2/12/2013                                                                             |   |   |                                                        | -      |   |   |   | 9,375  | (6)     |   |   | 9,375                                                      | (6)    |   |                                                             | -      |   |   |   | - |   |   |   | 70.37 |   |   |   | 522,750 |   |
|                         | 3/24/2014  |   | 8/16/2013                                                                             |   |   |                                                        | -      |   |   |   | 5,000  | (7)     |   |   | 5,000                                                      | (7)    |   |                                                             | -      |   |   |   | - |   |   |   | 106.75 |   |   |   | 193,300 |   |
|                         | 3/24/2014  |   | 2/28/2014                                                                             |   |   |                                                        | -      |   |   |   | 1,667  | (8)     |   |   | 1,667                                                      | (8)    |   |                                                             | -      |   |   |   | - |   |   |   | 138.66 |   |   |   | 85,283 |   |
|                         | 4/2/2014   |   | 4/2/2014                                                                              |   |   |                                                        | -      |   |   |   | 7,500  | (5)     |   |   | 7,500                                                      | (5)    |   |                                                             | -      |   |   |   | - |   |   |   | 102.22 |   |   |   | 380,925 |   |
|                         | 3/24/2014  |   | 2/4/2014                                                                              |   |   |                                                        | -      |   |   |   | -      |    |   |   | -                                                          |   |   |                                                             | 5,867  | (9) |   |   | - |   |   |   | - |   |   |   | 667,979 |   |
|                         | 12/10/2014 |   | 7/22/2014                                                                             |   |   |                                                        | -      |   |   |   | -      |    |   |   | -                                                          |   |   |                                                             | 6,000  | (10) |   |   | - |   |   |   | - |   |   |   | 813,060 |   |
|                         |       |   |                                                                                  |   |   |                                                        |   |   |   |   |   |    |   |   |                                                       |   |   |                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Shawn Tomasello              | 8/18/2014  |   |                                                                                  | n/a    |   |                                                        |   | -      |   |   |   | -       |   |   |                                                       | -      |   |                                                             |   | - |   |   |   | 100,000 | (11) |   |   | 121.89 |   |   |   | 5,798,690 |   |
|                         | 8/18/2014  |   |                                                                                  | n/a    |   |                                                        |   | -      |   |   |   | -       |   |   |                                                       | -      |   |                                                             |   | 62,500 | (12) |   |   | - |   |   |   | - |   |   |   | 7,618,125 |   |
|                         |       |   |                                                                                  |   |   |                                                        |   |   |   |   |   |    |   |   |                                                       |   |   |                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Heow Tan                     | 3/24/2014  |   | 5/7/2012                                                                              |   |   |                                                        | -      |   |   |   | 25,000 | (13)    |   |   | 25,000                                                     | (13)   |   |                                                             | -      |   |   |   | - |   |   |   | 27.05 |   |   |   | 2,196,250 |   |
|                         | 3/24/2014  |   | 10/26/2012                                                                            |   |   |                                                        | -      |   |   |   | 14,583 | (14)    |   |   | 14,583                                                     | (14)   |   |                                                             | -      |   |   |   | - |   |   |   | 61.60 |   |   |   | 891,021 |   |
|                         | 4/2/2014   |   | 4/2/2014                                                                              |   |   |                                                        | -      |   |   |   | 5,625  | (5)     |   |   | 5,625                                                      | (5)    |   |                                                             | -      |   |   |   | - |   |   |   | 102.22 |   |   |   | 285,694 |   |
|                         |       |   |                                                                                  |   |   |                                                        |   |   |   |   |   |    |   |   |                                                       |   |   |                                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Paula Boultbee               | 3/24/2014  |   | 4/17/2012                                                                             |   |   |                                                        | -      |   |   |   | 50,000 | (15)    |   |   | 50,000                                                     | (15)   |   |                                                             | -      |   |   |   | - |   |   |   | 25.94 |   |   |   | 4,443,000 |   |

|  (1) | The exercise price for options with performance conditions is the closing market price of the Company’s Common Stock on the date the Compensation Committee took formal action to grant the options. The accounting grant date is deemed the date annual performance conditions were established and communicated, at which time the options were considered granted under ASC 718. |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | The amounts shown reflect estimated payouts of performance-based stock options for 25% of the fourth annual vesting tranche of the four-year performance period beginning in fiscal 2010. Goals for 25% of the fourth year tranche were set during the year ended December 31, 2014. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | Of the amounts shown, 5,729 shares reflects estimated payouts of performance-based stock options for 25% of the second annual vesting tranche of the four-year performance period beginning in fiscal 2012. The remaining 17,188 shares reflects estimated payouts of performance-based stock options for 75% of the third annual vesting tranche of the four-year performance period beginning in fiscal 2012. Goals for the remaining 25% of the third year tranche and the corresponding fair value were not established until the quarter ended March 31, 2015 and are excluded from the above table. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4) | Of the amounts shown, 7,292 shares reflects estimated payouts of performance-based stock options for 25% of the second annual vesting tranche of the four-year performance period beginning in the 6 month transition period ended December 31, 2012. The remaining 21,875 shares reflects estimated payouts of performance-based stock options for 75% of the third annual vesting tranche of the four-year performance period beginning in the 6 month transition period ended December 31, 2012. Goals for the remaining 25% of the third year tranche and the corresponding fair value were not established until the quarter ended March 31, 2015 and are excluded from the above table. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5) | The amounts shown reflect estimated payouts of performance-based stock options for 75% of the first annual vesting tranche of the four-year performance period beginning in fiscal 2014. Goals for 25% of the first year tranche were not established until the quarter ended March 31, 2015 and are excluded from the above table. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (6) | Of the amounts shown, 2,344 shares reflects estimated payouts of performance-based stock options for 25% of the second annual vesting tranche of the four-year performance period beginning in fiscal 2013. The remaining 7,031 shares reflects estimated payouts of performance-based stock options for 75% of the third annual vesting tranche of the four-year performance period beginning in fiscal 2013. Goals for the remaining 25% of the third year tranche and the corresponding fair value were not established until the quarter ended March 31, 2015 and are excluded from the above table. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| (7) | Of the amounts shown, 2,917 shares reflects estimated payouts of performance-based stock options for 7/12 of the first annual vesting tranche of the four-year performance period beginning in fiscal 2013. The remaining 2,083 shares reflects estimated payouts of performance-based stock options for 5/12 of the second annual vesting tranche of the four-year performance period beginning in fiscal 2013. Goals for the remaining 7/12 of the second year tranche and the corresponding fair value were not established until the quarter ended March 31, 2015 and are excluded from the above table. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (8)  | The amounts shown reflect estimated payouts of performance-based stock options for 10/12 of the first annual vesting tranche of the four-year performance period beginning in fiscal 2014. Goals for the remaining 2/12 of the first year tranche and the corresponding fair value were not established until the quarter ended March 31, 2015 and are excluded from the above table.                                                                                                                                                                                                                                                                                                                                               |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (9)  | The amounts shown reflect estimated payouts of performance-based RSUs for 11/60 of the total 32,000 RSUs granted which vests 40% on the second anniversary of the award date, 40% on the fourth anniversary of the award date and 20% on the fifth anniversary of the award date. The amount shown reflects 5,867 shares of the total 12,800 shares for the first vesting tranche of the five-year performance period beginning in fiscal 2014 which vests on the second anniversary of the award date. Goals for the remaining 6,933 of the 12,800 shares in the first annual vesting tranche and the corresponding fair value were not established until the quarter ended March 31, 2015 and are excluded from the above table.  |
| (10) | The amounts shown reflect estimated payouts of performance-based RSUs for 6,000 RSUs granted, which vested on March 3, 2015, upon the achievement of certain performance criteria.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| (11) | The amounts shown reflect 100,000 time-based stock options granted to Ms. Tomasello upon the date of hire in August 2014. The option shares vest in a series of four equal and successive annual installments occurring on August 18, 2015, August 18, 2016, August 18, 2017 and August 18, 2018.                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| (12) | The amounts shown reflect 62,500 time-based RSUs granted to Ms. Tomasello upon the date of hire in August 2014. Of this amount, 12,500 RSUs vested on November 18, 2014 and the remaining RSUs will vest in the respective amounts of 16,666, 16,667 and 16,667 RSUs on the first, second and third anniversaries of the date of grant.                                                                                                                                                                                                                                                                                                                                                                                             |
| (13) | Of the amounts shown, 6,250 shares reflects estimated payouts of performance-based stock options for 25% of the second annual vesting tranche of the four-year performance period beginning in fiscal 2012. The remaining 18,750 shares reflects estimated payouts of performance-based stock options for 75% of the third annual vesting tranche of the four-year performance period beginning in fiscal 2012. Goals for the remaining 25% of the third year tranche and the corresponding fair value were not established until the quarter ended March 31, 2015 and are excluded from the above table.                                                                                                                           |
| (14) | Of the amounts shown, 3,646 shares reflects estimated payouts of performance-based stock options for 25% of the second annual vesting tranche of the four-year performance period beginning in the 6 month transition period ended December 31, 2012. The remaining 10,937 shares reflects estimated payouts of performance-based stock options for 75% of the third annual vesting tranche of the four-year performance period beginning in the 6 month transition period ended December 31, 2012. Goals for the remaining 25% of the third year tranche and the corresponding fair value were not established until the quarter ended March 31, 2015 and are excluded from the above table.                                       |
| (15) | Of the amounts shown, 12,500 shares reflects estimated payouts of performance-based stock options for 25% of the second annual vesting tranche of the four-year performance period beginning in fiscal 2012. The remaining 37,500 shares reflects estimated payouts of performance-based stock options for 75% of the third annual vesting tranche of the four-year performance period beginning in fiscal 2012. Ms. Boultbee served as the Company's Executive Vice President of Sales and Marketing until May 20, 2014.                                                                                                                                                                                                                |

----

Table of Contents

|                         |   |          |   |   | Option Awards                                                     |    |   | Stock Awards                                                        |   |
|------------------------------|--------|---------------|--------|--------|-------------------------------------------------------------------|---------|--------|---------------------------------------------------------------------|--------|
|                         |   | Grant Date    |   |   | Number of securities underlying unexercised options - exercisable |    |   | Number of securities underlying unexercised options - unexercisable |   |   | Equity incentive plan awards: number of securities underlying unexercised unearned options |   |   | Option Exercise Price ($) |   |   | Option expiration date |   |   | Number of Shares or Units of Stock That Have Not Vested (#) |   |   | Market Value of Shares or Units of Stock That Have Not Vested ($) |   |   | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) |   |   | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) |   |
| Robert W. Duggan             |   |          | -      |   |                                                              |    | -      |                                                                |   |   | - |   |   |   | - |   |   | $ | - |   |   |   | - |   |   |   | - |   |   | $  | - |   |   |   | - |   |   | $  | - |   |
|                         |   |          |   |   |                                                              |    |   |                                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Mahkam Zanganeh, D.D.S., MBA |   | 9/10/2008     |   |   |                                                              | 48,219  |   |                                                                |   | - |   |   |   | - |   |   |   | 2.30 |   |   | 09/10/2018 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 3/3/2009      |   |   |                                                              | 130,000 |   |                                                                |   | - |   |   |   | - |   |   |   | 0.75 |   |   | 03/03/2019 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 4/11/2010     |   |   |                                                              | 144,069 |   |                                                                |   | - |   |   |   | - |   |   |   | 7.19 |   |   | 04/11/2020 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 6/2/2010      |   |   |                                                              | 10,000  |   |                                                                |   | - |   |   |   | - |   |   |   | 6.75 |   |   | 06/02/2020 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 10/13/2010    |   |   |                                                              | 30,000  |   |                                                                |   | - |   |   |   | - |   |   |   | 7.69 |   |   | 10/13/2020 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 10/14/2010    |   |   |                                                              | 10,000  |   |                                                                |   | - |   |   |   | - |   |   |   | 7.48 |   |   | 10/14/2020 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 12/13/2010    |   |   |                                                              | 25,000  |   |                                                                |   | - |   |   |   | - |   |   |   | 5.81 |   |   | 12/13/2020 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 12/1/2011(1)  |   |   |                                                              | 54,167  |   |                                                                |   | 17,188 |   |   |   | 28,645 |   |   |   | 14.92 |   |   | 12/01/2021 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 10/26/2012(2) |   |   |                                                              | 41,667  |   |                                                                |   | 21,875 |   |   |   | 36,458 |   |   |   | 61.60 |   |   | 10/26/2022 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 4/2/2014(3)   |   |   |                                                              | -       |   |                                                                |   | 7,500 |   |   |   | 32,500 |   |   |   | 102.22 |   |   | 04/02/2024 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   |          |   |   |                                                              |    |   |                                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Manmeet S. Soni              |   | 10/26/2012(4) |   |   |                                                              | 10,250  |   |                                                                |   | 8,750 |   |   |   | - |   |   |   | 61.60 |   |   | 10/26/2022 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 2/12/2013(5)  |   |   |                                                              | 11,250  |   |                                                                |   | 7,031 |   |   |   | 11,719 |   |   |   | 70.37 |   |   | 02/12/2023 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 8/16/2013(6)  |   |   |                                                              | 5,000   |   |                                                                |   | 2,083 |   |   |   | 12,917 |   |   |   | 106.75 |   |   | 08/16/2023 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 2/28/2014(7)  |   |   |                                                              | -       |   |                                                                |   | 1,667 |   |   |   | 6,333 |   |   |   | 138.66 |   |   | 02/28/2024 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 4/2/2014(3)   |   |   |                                                              | -       |   |                                                                |   | 7,500 |   |   |   | 32,500 |   |   |   | 102.22 |   |   | 04/02/2024 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 2/4/2014(8)   |   |   |                                                              | -       |   |                                                                |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 32,000 |   |   |   | 3,912,320 |   |
|                         |   | 7/22/2014(9)  |   |   |                                                              | -       |   |                                                                |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 6,000 |   |   |   | 733,560 |   |
|                         |   |          |   |   |                                                              |    |   |                                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Shawn Tomasello              |   | 8/18/2014(10) |   |   |                                                              | -       |   |                                                                |   | 100,000 |   |   |   | - |   |   |   | 121.89 |   |   | 08/18/2024 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 8/18/2014(11) |   |   |                                                              | -       |   |                                                                |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | 50,000 |   |   |   | 6,113,000 |   |   |   | - |   |   |   | - |   |
|                         |   |          |   |   |                                                              |    |   |                                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Heow Tan                     |   | 5/7/2012(12)  |   |   |                                                              | 26,304  |   |                                                                |   | 18,750 |   |   |   | 31,250 |   |   |   | 27.05 |   |   | 05/07/2022 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 10/26/2012(2) |   |   |                                                              | 20,833  |   |                                                                |   | 10,937 |   |   |   | 18,230 |   |   |   | 61.60 |   |   | 10/26/2022 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   | 4/2/2014(3)   |   |   |                                                              | -       |   |                                                                |   | 5,625 |   |   |   | 24,375 |   |   |   | 102.22 |   |   | 04/02/2024 |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |
|                         |   |          |   |   |                                                              |    |   |                                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Paula Boultbee(13)           |   |          |   |   |                                                              |    | -      |                                                                |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |   |   | - |   |

| (1)  | Option vested 4/48 on June 28, 2012, 11/48 on April 11, 2013 and 11/48 on April 11, 2014. The remaining options vest 11/48 on April 11, 2015 and 11/48 on April 11, 2016, subject to satisfaction of certain performance criteria with respect to each annual period. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2)  | Option vested 6/48 on April 11, 2013 and 14/48 on April 11, 2014. The remaining options vest 14/48 on April 11, 2015 and 14/48 on April 11, 2016, subject to the satisfaction of certain performance criteria with respect to each annual period.                     |
| (3)  | Option vested 1/4 on April 2, 2015. The remaining options vest 1/4 on each of April 2, 2016, April 2, 2017 and April 2, 2018, subject to the satisfaction of certain performance criteria with respect to each annual period.                                         |
| (4)  | Option vested 12/48 on September 6, 2013. The remaining 36/48 is vesting evenly on a monthly basis from October 2013 until September 2016.                                                                                                                            |
| (5)  | Option vested 3/48 on April 11, 2013, and 15/48 on April 11, 2014. The remaining options vest 15/48 on April 11, 2015 and 15/48 on April 11, 2016, subject to the satisfaction of certain performance criteria with respect to each annual period.                    |
| (6)  | Option vested 1/4 on August 16, 2014 and the remainder will vest 1/4 on each of August 16, 2015, August 16, 2016 and August 16, 2017, subject to the satisfaction of certain performance criteria with respect to each annual period.                                 |
| (7)  | Option vests in four equal annual installments beginning February 28, 2015, subject to the satisfaction of certain performance criteria with respect to each annual period.                                                                                           |
| (8)  | RSU vests 40% on the second anniversary of the award date, 40% on the fourth anniversary of the award date and 20% on the fifth anniversary of the award date, with the vesting of each such tranche subject to the satisfaction of certain performance criteria.     |
| (9)  | Upon the achievement of performance criteria, this RSU grant fully vested on March 3, 2015.                                                                                                                                                                           |
| (10) | Option vests in a series of four equal and successive annual installments occurring on August 18, 2015, August 18, 2016, August 18, 2017 and August 18, 2018.                                                                                                         |
| (11) | Represents RSUs; 12,500 of which vested on November 18, 2014, and the remaining RSUs shall vest in the respective amounts of 16,666, 16,667 and 16,667 RSUs on the first, second and third anniversaries of the grant date.                                           |
| (12) | Option vests in four equal annual installments beginning April 11, 2013, subject to the achievement of certain performance criteria with respect to each annual period.                                                                                               |
| (13) | Ms. Boultbee served as the Company's Executive Vice President of Sales and Marketing until May 20, 2014.                                                                                                                                                              |

----

Table of Contents

|                         |   | Option Awards                         |   |   | Stock Awards                     |   |
|------------------------------|--------|---------------------------------------|--------|--------|----------------------------------|--------|
|                         |   | Number of shares acquired on exercise |   |   | Value realized on exercise (1) $ |   |   | Number of shares acquired on vesting |   |   | Value realized on vesting $ |   |
| Robert W. Duggan             |   |                                  | -      |   |                             | $      | - |   |   |   | - |   |   | $ | - |   |
| Mahkam Zanganeh, D.D.S., MBA |   |                                  | 42,482 |   |                             |   | 5,439,911 |   |   |   | - |   |   |   | - |   |
| Manmeet Soni                 |   |                                  | 1,000  |   |                             |   | 79,842 |   |   |   | - |   |   |   | - |   |
| Shawn Tomasello              |   |                                  | -      |   |                             |   | - |   |   |   | 12,500 |   |   |   | 1,713,375 |   |
| Heow Tan                     |   |                                  | 12,196 |   |                             |   | 1,166,220 |   |   |   | - |   |   |   | - |   |
| Paula Boultbee(2)            |   |                                  | 87,500 |   |                             |   | 7,235,481 |   |   |   | - |   |   |   | - |   |

| (1) | Value realized on exercise is based on the fair market value of our common stock on the date of exercise minus the exercise price and does not necessarily reflect proceeds actually received by the named executive officer. The value realized on vesting of RSUs represents the number of shares vested multiplied by the closing per share price of our common stock on the date of vest. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Ms. Boultbee served as the Company’s Executive Vice President of Sales and Marketing until May 20, 2014.                                                                                                                                                                                                                                                                                |

----

Table of Contents

|                     |   | Fees Earned or |   |   |          |   |    |   |   |
|--------------------------|--------|----------------|--------|--------|---------------|--------|---------|--------|--------|
|                     |   | Paid in Cash   |   |   | Option Awards |   |    | Total  |   |
| Current Directors:       |   | ($) (1)        |   |   | ($) (2)       |   |    | ($)    |   |
| Robert W. Duggan         |   | $              | -      |   |          | $      | -       |   |   | $ | - |   |
| Robert F. Booth, Ph.D.   |   |           | -      |   |          |   | 240,203 |   |   |   | 240,203 |   |
| Kenneth A. Clark         |   |           | -      |   |          |   | 232,005 |   |   |   | 232,005 |   |
| Eric H. Halvorson        |   |           | -      |   |          |   | 243,699 |   |   |   | 243,699 |   |
| Minesh P. Mehta, M.D.    |   |           | -      |   |          |   | 230,977 |   |   |   | 230,977 |   |
| David D. Smith, Ph.D.    |   |           | -      |   |          |   | 238,826 |   |   |   | 238,826 |   |
| Richard A. van den Broek |   |           | -      |   |          |   | 246,347 |   |   |   | 246,347 |   |

| (1) | See the section entitled “Director Compensation - Cash Compensation”, above, for a description of the cash compensation program for the Company’s non-employee directors during the fiscal year ended December 31, 2014. Amounts earned in one year and paid in the following year are accounted for in the year earned. For fees earned during the year ended December 31, 2014, directors elected to receive option shares in lieu of such fees. The following directors received option shares in lieu of the fees set forth below: |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Directors                |   | Annual RetainerFees Foregone(3) |    |   | QuarterlyFees Foregone(3) |   |   | Option SharesReceived in Lieu of Cash |   |   | Option Shares Granted |   |
|--------------------------|--------|---------------------------------|---------|--------|---------------------------|--------|--------|---------------------------------------|--------|--------|-----------------------|--------|
| Robert F. Booth, Ph.D.   |   | $                               | 31,000  |   |                      | $      | 15,000 |                                  |   |   | 1,272                 |   |   |   | 5,022 |   |
| Kenneth A. Clark         |   |                            | 28,000  |   |                      |   | 12,000 |                                  |   |   | 1,109                 |   |   |   | 4,859 |   |
| Eric Halvorson, J.D.     |   |                            | 33,000  |   |                      |   | 15,500 |                                  |   |   | 1,340                 |   |   |   | 5,090 |   |
| Minesh P. Mehta, M.D.    |   |                            | 30,000  |   |                      |   | 9,500  |                                  |   |   | 1,100                 |   |   |   | 4,850 |   |
| David D. Smith, Ph.D.    |   |                            | 30,000  |   |                      |   | 15,000 |                                  |   |   | 1,245                 |   |   |   | 4,995 |   |
| Richard A. van den Broek |   |                            | 33,000  |   |                      |   | 17,500 |                                  |   |   | 1,392                 |   |   |   | 5,142 |   |
|                     |   | $                               | 185,000 |   |                      | $      | 84,500 |                                  |   |   | 7,458                 |   |   |   | 29,958 |   |

| (2) | The amounts set forth under this column represent the aggregate grant date fair value of stock options earned in the fiscal year ended December 31, 2014 for financial reporting purposes under Statement of Financial Accounting Standards ASC Topic 718, “Stock Compensation,” disregarding the estimate of forfeitures. The Company’s methodology, including its underlying estimates and assumptions used in calculating these values, is set forth in Note 9 to its audited financial statements included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission for the fiscal year ended December 31, 2014. See the section entitled “Director Compensation - Equity Compensation”, above, for a description of the Company’s cash compensation policy for non-employee directors and the specific terms of the stock options granted to the Company’s non-employee directors during the fiscal year ended December 31, 2014. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | Amounts earned in one year and paid in the following year are accounted for in the year earned. |
|-----|-------------------------------------------------------------------------------------------------|

----

Table of Contents

| Directors                | GrantDate                                |   | Grant DateFair Value |   |    | OptionsOutstanding at 12/31/14 |   |
|--------------------------|------------------------------------------|--------|----------------------|--------|---------|--------------------------------|--------|
| Robert F. Booth, Ph.D.   | 4/1/2014                                 |   |                 | $      | 12,706  |                           |   |   |   |
|                     | 5/9/2014                                 |   |                 |   | 175,730 |                           |   |   |   |
|                     | 7/1/2014                                 |   |                 |   | 18,182  |                           |   |   |   |
|                     | 10/1/2014                                |   |                 |   | 16,834  |                           |   |   |   |
|                     |       1/2/2015       | (1)    |                 |   | 16,751  |                           |   |   |   |
|                     |                                     |   |                 | $      | 240,203 |                           |   |   | 66,255 |   |
|                     |                                     |   |                 |   |    |                           |   |   |   |   |
| Kenneth A. Clark         | 4/1/2014                                 |   |                 | $      | 10,271  |                           |   |   |   |   |
|                     | 5/9/2014                                 |   |                 |   | 175,730 |                           |   |   |   |   |
|                     | 7/1/2014                                 |   |                 |   | 15,738  |                           |   |   |   |   |
|                     | 10/1/2014                                |   |                 |   | 15,226  |                           |   |   |   |   |
|                     |       1/2/2015       | (1)    |                 |   | 15,040  |                           |   |   |   |   |
|                     |                                     |   |                 | $      | 232,005 |                           |   |   | 24,355 |   |
|                     |                                     |   |                 |   |    |                           |   |   |   |   |
| Eric Halvorson, J.D.     | 4/1/2014                                 |   |                 | $      | 14,136  |                           |   |   |   |   |
|                     | 5/9/2014                                 |   |                 |   | 175,730 |                           |   |   |   |   |
|                     | 7/1/2014                                 |   |                 |   | 18,868  |                           |   |   |   |   |
|                     | 10/1/2014                                |   |                 |   | 17,531  |                           |   |   |   |   |
|                     |        1/2/2015 | (1)    |                 |   | 17,434  |                           |   |   |   |   |
|                     |                                     |   |                 | $      | 243,699 |                           |   |   | 31,168 |   |
|                     |                                     |   |                 |   |    |                           |   |   |   |   |
| Minesh P. Mehta, M.D.    | 4/1/2014                                 |   |                 | $      | 8,312   |                           |   |   |   |   |
|                     | 5/9/2014                                 |   |                 |   | 175,730 |                           |   |   |   |   |
|                     | 7/1/2014                                 |   |                 |   | 17,453  |                           |   |   |   |   |
|                     | 10/1/2014                                |   |                 |   | 16,834  |                           |   |   |   |   |
|                     |        1/2/2015 | (1)    |                 |   | 12,648  |                           |   |   |   |   |
|                     |                                     |   |                 | $      | 230,977 |                           |   |   | 29,909 |   |
|                     |                                     |   |                 |   |    |                           |   |   |   |   |
| David D. Smith, Ph.D.    | 4/1/2014                                 |   |                 | $      | 12,336  |                           |   |   |   |   |
|                     | 5/9/2014                                 |   |                 |   | 175,730 |                           |   |   |   |   |
|                     | 7/1/2014                                 |   |                 |   | 17,839  |                           |   |   |   |   |
|                     | 10/1/2014                                |   |                 |   | 16,513  |                           |   |   |   |   |
|                     |       1/2/2015  | (1)    |                 |   | 16,408  |                           |   |   |   |   |
|                     |                                     |   |                 | $      | 238,826 |                           |   |   | 181,822 |   |
|                     |                                     |   |                 |   |    |                           |   |   |   |   |
| Richard A. van den Broek | 4/1/2014                                 |   |                 | $      | 14,824  |                           |   |   |   |   |
|                     | 5/9/2014                                 |   |                 |   | 175,730 |                           |   |   |   |   |
|                     | 7/1/2014                                 |   |                 |   | 19,555  |                           |   |   |   |   |
|                     | 10/1/2014                                |   |                 |   | 18,121  |                           |   |   |   |   |
|                     |       1/2/2015  | (1)    |                 |   | 18,117  |                           |   |   |   |   |
|                     |                                     |   |                 | $      | 246,347 |                           |   |   | 100,024 |   |
|                     |                                     |   |                 |   |    |                           |   |   |   |   |

----

Table of Contents

| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |
|----------|------------------------------------------------------------------------------------------------|

|  Plan Category                                   |   | Number of securities tobe issued upon exerciseof outstanding options,warrants and rights (a)(1) |   |   | Weighted-averageexercise price ofoutstanding options,warrants and rights (b)(2) |   |   | Number of securitiesremaining available forfuture issuance underequity compensationplans (excludingsecurities reflected incolumn (a)) (c) (3) |   |
|------------------------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------|--------|--------|-----------------------------------------------------------------------------------------------------|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| Equity compensation plans approved by security holders (4) |   |  5,241,852                                                                                                |   |   |                                                                                                | $49.67 |   |                                                                                                                                                    |   |   | 2,417,525 |    |
| Equity compensation plans not approved by security holders |   |  -                                                                                                        |   |   |                                                                                                | -      |   |                                                                                                                                                    |   |   | - |    |
| Total                                                      |   |  5,241,852                                                                                                |   |   |                                                                                                | $49.67 |   |                                                                                                                                                    |   |   | 2,417,525 |    |

|   | (1) | Includes 5,008,752 shares subject to outstanding options issuable under our 2014 Plan and 2004 Plan and 233,100 shares subject to outstanding RSUs issuable under our 2014 and 2004 Plan. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | (2) | This weighted-average exercise price does not include outstanding restricted stock units.                                                                                                 |
|   | (3) | Includes approximately 1,963,179 shares issuable under the Company’s 2014 Plan and 454,346 shares issuable under the Company’s Employee Stock Purchase Plan.                  |

|   | (4)     | Includes our: |
|--------|---------|---------------|
|   | • |          | 2014 Plan |
|   | • |          | 2004 Plan |
|   | • |          | Employee Stock Purchase Plan |

----

Table of Contents

|                                                                                                                     |   | Beneficial Ownership (1)                          |       |
|--------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------------|------------|
|  Name                                                                                                          |   | Number of SharesBeneficially Owned |       |   | Percent ofTotal SharesOutstanding |   |
| T. Rowe Price Associates, Inc. (2)    100 E. Pratt Street    Baltimore, MD 21202           |   |                                              | 9,886,484  |   |   |   | 12.9 | % |
| Baker Bros. Advisors, LP (3)    667 Madison Avenue, 21st Floor    New York, NY 10065       |   |                                              | 9,129,231  |   |   |   | 11.9 | % |
| Ameriprise Financial, Inc. (4)    145 Ameriprise Financial Center    Minneapolis, MN 55474 |   |                                              | 4,968,834  |   |   |   | 6.5 | % |
| Janus Capital Management LLC (5)    151 Detroit Street    Denver, CO 80206                 |   |                                              | 4,873,223  |   |   |   | 6.3 | % |
| Robert W. Duggan (6)                                                                                                     |   |                                              | 13,599,690 |   |   |   | 17.7 | % |
| Robert F. Booth, Ph.D. (7)                                                                                               |   |                                              | 60,549     |   |   |   | * |   |
| Minesh P. Mehta, M.D. (8)                                                                                                |   |                                              | 30,131     |   |   |   | * |   |
| David D. Smith, Ph.D. (9)                                                                                                |   |                                              | 185,110    |   |   |   | * |   |
| Richard A. van den Broek (10)                                                                                            |   |                                              | 125,952    |   |   |   | * |   |
| Eric H. Halvorson (11)                                                                                                   |   |                                              | 26,474     |   |   |   | * |   |
| Kenneth A. Clark (12)                                                                                                    |   |                                              | 15,619     |   |   |   | * |   |
| Mahkam Zanganeh, D.D.S., MBA (13)                                                                                        |   |                                              | 812,506    |   |   |   | 1.1 | % |
| Manmeet S. Soni (14)                                                                                                     |   |                                              | 26,471     |   |   |   | * |   |
| Heow Tan (15)                                                                                                            |   |                                              | 97,290     |   |   |   | * |   |
| Shawn Tomasello (16)                                                                                                     |   |                                              | 7,312      |   |   |   | * |   |
| Paula Boultbee (17)                                                                                                      |   |                                              | 7,914      |   |   |   | * |   |
| All current executive officers and directors as a group (11 persons) (18)                                 |   |                                              | 14,987,104 |   |   |   | 19.5 | % |

----

| (1) | Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Beneficial ownership also includes shares of stock subject to options which are vested and exercisable within sixty (60) days of the March 31, 2015, the date of this table. Except as indicated by footnote, and subject to community property laws where applicable, to the knowledge of the Company, all persons named in the table above have sole voting and investment power with respect to all shares of Common Stock shown as beneficially owned by such holders. The percentages of beneficial ownership are based on 76,791,635 shares of Common Stock outstanding as of March 31, 2015, adjusted as required by rules promulgated by the Commission. For purposes of computing the percentage of outstanding shares held by each person or group of persons named above on a given date, any shares which such person or persons has the right to acquire within sixty (60) days after such date are deemed to be outstanding, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| (2) | Derived from a Form 13G/A filed on February 13, 2015. These securities are owned by various individual and institutional investors which T. Rowe Price Associates, Inc. (Price Associates) serves as an investment adviser with power to direct investments and/or sole power to vote the securities. For the purposes of the reporting requirements of the Securities Exchange Act of 1934, Price Associates is deemed to be a beneficial owner of such securities; however, Price Associates expressly disclaims that it is, in fact, the beneficial owner of such securities.  |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | Derived from a Form 13G/A filed February 17, 2015.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | Derived from a Form 13G filed February 17, 2015.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| (5) | Derived from a Form 13G filed February 18, 2015.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| (6) | Derived from a Form 5 dated February 11, 2015, adjusted for 152,635 shares gifted on March 13, 2015 and 4,785 shares gifted on March 17, 2015. Includes (i) 1,020,756 shares owned by Mr. Duggan’s spouse; (ii) 5,421 shares owned by Blazon Corp. (“Blazon”), as the sole stockholder of Blazon, Mr. Duggan may be deemed to beneficially own the shares owned by Blazon; (iii) 283,074 shares owned by MultiAccess Computing Corp. (“MultiAccess”), as the sole stockholder of MultiAccess, Mr. Duggan may be deemed to beneficially own the shares owned by MultiAccess, (iv) 161,760 shares held in irrevocable trusts for the benefit of Mr. Duggan’s children (for which neither Mr. Duggan nor any immediate family members of Mr. Duggan are trustees); (v) 42,020 shares directly owned by certain of Mr. Duggan’s children; and (vi) 170,379 shares held in managed accounts. Mr. Duggan disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.  |
| (7) | Represents 60,549 shares that Dr. Booth has the right to acquire within 60 days of March 31, 2015 through the exercise of stock options.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

| (8) | Represents 30,131 shares that Dr. Mehta has the right to acquire within 60 days of March 31, 2015 through the exercise of stock options. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------|

| (9) | Includes 182,110 shares that Dr. Smith has the right to acquire within 60 days of March 31, 2015 through the exercise of stock options. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------|

| (10) | Includes 29,610 shares directly owned by HSMR Advisors, LLC, of which Mr. van den Broek is the managing partner. Also includes 96,342 shares that Mr. van den Broek has the right to acquire within 60 days of March 31, 2015 through the exercise of stock options. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (11) | Includes 25,474 shares that Mr. Halvorson has the right to acquire within 60 days of March 31, 2015 through the exercise of stock options. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------|

| (12) | Represents 15,619 shares that Mr. Clark has the right to acquire within 60 days of March 31, 2015 through the exercise of stock options. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------|

| (13) | Includes 75,363 shares that Dr. Zanganeh serves as a custodian for a minor child. Also includes 384,487 shares that Dr. Zanganeh has the right to acquire within 60 days of March 31, 2015 through the exercise of stock options. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  (14) | Includes 25,860 shares that Mr. Soni has the right to acquire within 60 days of March 31, 2015 through the exercise of stock options. |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------|

| (15) | Includes 89,524 shares that Mr. Tan has the right to acquire within 60 days of March 31, 2015 through the exercise of stock options. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------|

| (16) | Represents 7,312 shares owned by Ms. Tomasello as of March 31, 2015. Ms. Tomasello has the right to acquire zero shares within 60 days of March 31, 2015 through the exercise of stock options or vesting of restricted stock units based on the vest schedule of such stock-based awards. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (17) | Ms. Boultbee served as the Company’s Executive Vice President of Sales and Marketing until May 20, 2014. |
|------|----------------------------------------------------------------------------------------------------------------|

| (18) | Includes 910,096 shares in the aggregate that our current executive officers and directors have the right to acquire within 60 days of March 31, 2015 through the exercise of stock options. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Item 13. | Certain Relationships and Related Transactions, and Director Independence |
|----------|---------------------------------------------------------------------------|

----

Table of Contents

| Directors:                 |   | Board    |   | AuditCommittee |   | CompensationCommittee |   | NominatingandCorporateGovernanceCommittee |
|----------------------------|--------|----------|--------|----------------|--------|-----------------------|--------|-------------------------------------------|
| Robert W. Duggan |   | Chairman |   |           |   |                  |   |                                      |
| Robert F. Booth, Ph.D.     |   | Member   |   |           |   |                  |   | Chairman                                  |
| Kenneth A. Clark           |   | Member   |   |           |   |                  |   |                                      |
| Eric H. Halvorson          |   | Member   |   | Chairman       |   | Member                |   | Member                                    |
| Minesh P. Mehta, M.D.      |   | Member   |   | Member         |   |                  |   |                                      |
| David D. Smith, Ph.D.      |   | Member   |   |           |   | Member                |   | Member                                    |
| Richard A. van den Broek   |   | Member   |   | Member         |   | Chairman              |   | Member                                    |

| Item 14. | Principal Accountant Fees and Services |
|----------|----------------------------------------|

|               |   | Fiscal 2014 |      |   | Fiscal 2013 |   |
|--------------------|--------|-------------|-----------|--------|-------------|--------|
| Audit fees         |   | $           | 1,683,828 |   |        | $      | 1,569,810 |   |
| Audit-related fees |   |        | –   |   |        |   | – |   |
| Tax fees           |   |        | 31,620    |   |        |   | 318,983 |   |
| All other fees     |   |        | 2,600     |   |        |   | 10,600 |   |
| Total              |   | $           | 1,718,048 |   |        | $      | 1,899,393 |   |

----

Table of Contents

PART 

| Item 15. | Exhibits and Financial Statement Schedules |
|----------|--------------------------------------------|

| 1. | Financial Statements: |
|----|-----------------------|

| 2. | Financial Statement Schedules: |
|----|--------------------------------|

| 3. | Exhibits |
|----|----------|

----

Table of Contents

|   | PHARMACYCLICS, INC. |
|--------|---------------------|
|   |                |
|   |                |
|   |                |
|   | By:                 | /s/ Robert W. Duggan |
|   |                | Name: | Robert W. Duggan |
|   |                | Title: | Chairman of the Board andChief Executive Officer |

|    By: | /s/ Robert W. Duggan                                                                                | April 8, 2015 |
|-----------------------|-----------------------------------------------------------------------------------------------------|---------------|
|                  | Robert W. Duggan, Chairman of the Board and Chief Executive Officer (Principal Executive Officer)   |          |
|                  |                                                                                                |          |
|    By: | /s/ Manmeet S. Soni                                                                                 | April 8, 2015 |
|                  | Manmeet S. Soni, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) |          |
|                  |                                                                                                |          |
|    By: | *                                                                                                   | April 8, 2015 |
|                  | Robert F. Booth, Ph.D., Director                                                                    |          |
|                  |                                                                                                |          |
|    By: | *                                                                                                   | April 8, 2015 |
|                  | Kenneth A. Clark, Director                                                                          |          |
|                  |                                                                                                |          |
|    By: | *                                                                                                   | April 8, 2015 |
|                  | Eric H. Halvorson., Director                                                                        |          |
|                  |                                                                                                |          |
|    By: | *                                                                                                   | April 8, 2015 |
|                  | Minesh P. Mehta, M.D., Director                                                                     |          |
|                  |                                                                                                |          |
|    By: | *                                                                                                   | April 8, 2015 |
|                  | David D. Smith, Ph.D.                                                                               |          |
|                  |                                                                                                |          |
|    By: | *                                                                                                   | April 8, 2015 |
|                  | Richard A. van den Broek                                                                            |          |
|                  |                                                                                                |          |
| * By:                 | /s/ Manmeet S. Soni,                                                                                | April 8, 2015 |
|                  | * Manmeet S. Soni, Attorney-in-fact                                                                 |          |

----

Table of Contents

| Exhibit Number |   | Description                                                                                                                                                                                                                                                                                                               |
|----------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2.1            |   | Agreement and Plan of Reorganization, dated as of March 4, 2015, by and among AbbVie Inc., Oxford Amherst Corporation, Oxford Amherst LLC and the Company (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2015. |
| 3.1            |   | Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 16, 2008).                                                                                     |
| 3.2            |   | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 19, 2011).                                                     |
| 3.3            |   | Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 19, 2011).                                                                                                           |
| 3.4            |   | Amendment to the Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2015).                                                                                              |
| 4.1            |   | Specimen Certificate of the Company's Common Stock (incorporated by reference to Exhibit 4.2 to the Company's Registration Statement on Form S-1, Commission File No. 33-96048).                                                                                                                                          |
| 10.1+          |   | The Company's Employee Stock Purchase Plan as amended and restated on October 25, 2011 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 19, 2011).                                                              |
| 10.2+          |   | Form of Employee Stock Purchase Plan Enrollment/Change Form (incorporated by reference to Exhibit 99.12 to the Company's Registration Statement on Form S-8, Commission File No. 33-98514).                                                                                                                               |
| 10.3           |   | Lease and Lease Termination Agreement dated June 14, 2000 by and between the Company and Metropolitan Life Insurance Company (incorporated by reference to Exhibit 10.49 to the Annual Report on Form 10-K for the year ended June 30, 2001).                                                                             |
| 10.4           |   | First Amendment to New Lease dated April 10, 2001 by and between the Company and Metropolitan Life Insurance Company (incorporated by reference to Exhibit 10.50 to the Annual Report on Form 10-K for the year ended June 30, 2001).                                                                                     |
| 10.5           |   | Second Amendment to New Lease dated June 29, 2001 by and between the Company and Metropolitan Life Insurance Company (incorporated by reference to Exhibit 10.51 to the Annual Report on Form 10-K for the year ended June 30, 2001).                                                                                     |
| 10.6           |   | Third Amendment to New Lease dated February 5, 2003 by and between the Company and Metropolitan Life Insurance Company (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2003).                                                                             |
| 10.7+          |   | The Company's 2004 Equity Incentive Award Plan (the "2004 Plan") as amended and restated on October 25, 2011 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 19, 2011).                                        |
| 10.8+          |   | The Company’s 2014 Equity Incentive Award Plan (the “2014 Plan”) (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 14, 2014).                                                                       |
| 10.9+          |   | Form of Option Agreement.                                                                                                                                                                                                                                                                                                 |

----

Table of Contents

|  10.10* |   | Assignment Agreement By and Between Pharmacyclics, Inc. and Applera Corporation dated April 7, 2006 (incorporated by reference to Exhibit 10.64 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2006).                                                                                                  |
|--------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.11        |   | Fourth Amendment to New Lease dated August 14, 2006 by and between the Company and Metropolitan Life Insurance Company (incorporated by reference to Exhibit 10.5 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 17, 2006).                                         |
| 10.12        |   | Fifth Amendment to New Lease dated July 11, 2008 by and between the Company and Metropolitan Life Insurance Company (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 15, 2008).                                        |
|  10.13* |   | Amendment No. 1 to Assignment Agreement by and between Pharmacyclics, Inc. and Applera Corporation dated May 12, 2008 (incorporated by reference to Exhibit 10.68 to the Company’s Annual Report on Form 10-K for the year ended June 30, 2008).                                                                       |
|  10.14* |   | Amendment No. 2 to Assignment Agreement by and between Pharmacyclics, Inc. and Celera Corporation dated March 2, 2009 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009).                                                                                 |
|  10.15* |   | Amendment No. 3 to Assignment Agreement by and between Pharmacyclics, Inc. and Celera Corporation dated March 30, 2009 (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009).                                                                                |
|  10.16* |   | Collaboration Agreement by and between Pharmacyclics, Inc. and Les Laboratoires Servier and Institut de Recherches Internationales Servier dated April 9, 2009 (incorporated by reference to Exhibit 10.83 to the Company’s Annual Report on Form 10-K for the year ended June 30, 2009).                              |
|  10.17* |   | Drug Supply Agreement by and between Pharmacyclics, Inc. and Les Laboratoires Servier dated December 18, 2009 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q for the quarter ended December 31, 2009).                                                                                      |
| 10.18        |   | Sixth Amendment to New Lease dated January 20, 2011 by and between the Company and Metropolitan Life Insurance Company (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2011).                                                                                |
|  10.19* |   | Collaboration and License Agreement by and between the Company and Janssen Biotech, Inc. dated as of December 8, 2011 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q for the quarter ended December 31, 2011).                                                                              |
| 10.20        |   | Seventh Amendment to New Lease dated February 14, 2012 by and between the Company and Metropolitan Life Insurance Company (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012).                                                             |
| 10.21        |   | Amendment No. 1 to the Collaboration Agreement by and between the Company and Les Laboratoires Servier and Institut De Recherches Internationales Servier dated as of January 5, 2012 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012). |
| 10.22*       |   | Amended and Restated License Agreement by and between the Company and Novo Nordisk A/S, dated as of June 28, 2013 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2013).                                                                            |
| 10.23*       |   | Manufacturing Supply Agreement by and between the Company and Lonza Sales Ltd., dated February 5, 2013 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K/A filed with the Securities and Exchange Commission on August 14, 2014).                                                 |
| 10.24*       |   | Amendment One to Manufacturing Supply Agreement by and between the Company and Lonza Sales Ltd., dated October 2, 2013 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K/A filed with the Securities and Exchange Commission on August 14, 2014).                                 |

----

Table of Contents

|    10.25*              |   | Build Out and Commercial Supply Agreement by and between the Company and Catalent CTS, LLC dated May 1, 2013 (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K/A filed with the Securities and Exchange Commission on August 14, 2014).                                                                                                                                             |
|----------------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.26                            |   | First Amendment to the Company's Employee Stock Purchase Plan, as amended January 21, 2014 (incorporated by reference to Exhibit 10.38 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013).                                                                                                                                                                                                |
| 10.27                            |   | Second Amendment to the Company's Employee Stock Purchase Plan, as amended January 21, 2014 (incorporated by reference to Exhibit 10.39 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013).                                                                                                                                                                                               |
| 10.28                            |   | Eighth Amendment to New Lease dated February 14, 2012 by and between the Company and Metropolitan Life Insurance Company (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012).                                                                                                                                                                |
| 10.29                            |   | Commercial Lease Agreement by and between the Company and John G. and Theresa L. Hessler as Trustees of the Hessler 2007 Revocable Trust; Mark Dellamano, John Dellamano and Joseph Dellamano, as Tenants in Common (incorporated by reference to Exhibit 10.41 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013).                                                                       |
| 10.30                            |   | Binding Notice to Landlord to Exercise Expansion Option pursuant to Section 1.6 of the Commercial Lease between the Company and John G. and Theresa L. Hessler as Trustees of the Hessler 2007 Revocable Trust; Mark Dellamano, John Dellamano and Joseph Dellamano, as Tenants in Common (incorporated by reference to Exhibit 10.42 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013). |
| 10.31                            |   | Form of Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.43 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013).                                                                                                                                                                                                                                                   |
| 10.32                            |   | Termination Letter dated September 24, 2014, by and between the Company and Les Laboratoires Servier and Institut de Recherches Internationales Servier (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014).                                                                                                                                                                |
|      10.33** |   | Letter re: Servier’s Termination Commitments dated September 24, 2014, by and between the Company and Les Laboratoires Servier and Institut de Recherches Internationales Servier (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014).                                                                                                                                |
| 10.34                            |   | Offer Letter effective as of August 18, 2014 by and between the Company and Shawn Tomasello (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014).                                                                                                                                                                                                                            |
| 10.35                            |   | Support Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2015).                                                                                                                                                                                                                                            |
| 10.36                            |   | Form of the Company’s Change in Control and Severance Plan (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2015).                                                                                                                                                                                             |
| 21.1                             |   | Subsidiaries of the Company (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014).                                                                                                                                                                                                                                                                                            |
| 23.1                             |   | Consent of Independent Registered Public Accounting Firm (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014).                                                                                                                                                                                                                                                               |
| 24.1                             |   | Power of Attorney (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014).                                                                                                                                                                                                                                                                                                      |
| 31.1                             |   | Certification of Principal Executive Officer.                                                                                                                                                                                                                                                                                                                                                                                  |
| 31.2                             |   | Certification of Principal Financial Officer.                                                                                                                                                                                                                                                                                                                                                                                  |
| 32.1                             |   | Certification of Principal Executive Officer and Principal Financial Officer (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014).                                                                                                                                                                                                                                           |
| 101.INS                          |   | XBRL Instance Document (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014).                                                                                                                                                                                                                                                                                                 |

----

Table of Contents

| 101.SCH |   | XBRL Taxonomy Extension Schema Document (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014).                |
|---------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 101.CAL |   | XBRL Taxonomy Extension Calculation Linkbase Document (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014).  |
| 101.DEF |   | XBRL Taxonomy Extension Definition Linkbase Document (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014).   |
| 101.LAB |   | XBRL Taxonomy Extension Label Linkbase Document (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014).        |
| 101.PRE |   | XBRL Taxonomy Extension Presentation Linkbase Document (filed with the initial filing of the Annual Report on Form 10-K for the year ended December 31, 2014). |